Canada Post Corp Registered Pension Plan Buys 1,486 Shares of Amgen Inc. $AMGN

Canada Post Corp Registered Pension Plan grew its stake in Amgen Inc. (NASDAQ:AMGN) by 16.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,400 shares of the medical research company’s stock after purchasing an additional 1,486 shares during the period. Canada Post Corp Registered Pension Plan’s holdings in Amgen were worth $2,849,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Ironwood Investment Counsel LLC grew its position in Amgen by 15.2% during the third quarter. Ironwood Investment Counsel LLC now owns 15,934 shares of the medical research company’s stock worth $4,497,000 after buying an additional 2,107 shares in the last quarter. Concord Wealth Partners raised its holdings in Amgen by 2.5% in the 3rd quarter. Concord Wealth Partners now owns 9,700 shares of the medical research company’s stock valued at $2,737,000 after acquiring an additional 233 shares in the last quarter. Fortitude Advisory Group L.L.C. lifted its position in shares of Amgen by 5.1% in the 3rd quarter. Fortitude Advisory Group L.L.C. now owns 1,293 shares of the medical research company’s stock worth $365,000 after acquiring an additional 63 shares during the period. DDFG Inc grew its holdings in shares of Amgen by 1.1% during the 3rd quarter. DDFG Inc now owns 3,014 shares of the medical research company’s stock worth $850,000 after purchasing an additional 34 shares in the last quarter. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd increased its position in shares of Amgen by 39.3% during the third quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 1,251 shares of the medical research company’s stock valued at $353,000 after purchasing an additional 353 shares during the period. Institutional investors own 76.50% of the company’s stock.

Amgen Price Performance

Shares of Amgen stock opened at $384.20 on Friday. The stock has a market capitalization of $206.88 billion, a price-to-earnings ratio of 27.00, a P/E/G ratio of 3.90 and a beta of 0.46. The firm’s 50-day moving average price is $334.45 and its two-hundred day moving average price is $311.49. The company has a current ratio of 1.14, a quick ratio of 0.99 and a debt-to-equity ratio of 5.78. Amgen Inc. has a 1-year low of $261.43 and a 1-year high of $385.12.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping the consensus estimate of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The business had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. During the same period in the previous year, the business earned $5.31 EPS. Amgen’s revenue was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, equities analysts predict that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 13th will be given a dividend of $2.52 per share. This is a positive change from Amgen’s previous quarterly dividend of $2.38. The ex-dividend date is Friday, February 13th. This represents a $10.08 annualized dividend and a yield of 2.6%. Amgen’s dividend payout ratio is currently 66.90%.

Insiders Place Their Bets

In other news, SVP Rachna Khosla sold 890 shares of the stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $336.24, for a total transaction of $299,253.60. Following the sale, the senior vice president directly owned 7,082 shares of the company’s stock, valued at $2,381,251.68. This represents a 11.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Nancy A. Grygiel sold 3,139 shares of the firm’s stock in a transaction that occurred on Thursday, November 20th. The shares were sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the completion of the sale, the senior vice president directly owned 7,225 shares of the company’s stock, valued at approximately $2,436,703.50. This represents a 30.29% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 10,908 shares of company stock valued at $3,674,966 in the last 90 days. 0.76% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of research firms have weighed in on AMGN. Morgan Stanley lifted their price target on shares of Amgen from $304.00 to $309.00 and gave the stock an “equal weight” rating in a research note on Wednesday. Oppenheimer set a $400.00 target price on shares of Amgen and gave the company an “outperform” rating in a research report on Thursday, January 29th. TD Cowen reissued a “buy” rating on shares of Amgen in a research note on Wednesday. Erste Group Bank upgraded shares of Amgen from a “hold” rating to a “buy” rating in a research note on Friday, December 5th. Finally, BMO Capital Markets upped their price objective on Amgen from $335.00 to $372.00 and gave the company an “outperform” rating in a research note on Wednesday, December 3rd. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Amgen currently has a consensus rating of “Moderate Buy” and an average price target of $351.65.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Argus raised its price target to $400 and reiterated a Buy rating, signaling analyst confidence in Amgen’s outlook and providing fresh positive momentum for the stock. Read More.
• Positive Sentiment: Q4 results beat Street estimates and management’s commentary pushed the shares to a new 12‑month high — the earnings beat and upgraded FY‑2026 guidance underpin the rally. Read More.
• Positive Sentiment: Clinical progress: Amgen advanced xaluritamig into a first‑in‑human Phase 1b trial for hard‑to‑treat Ewing sarcoma — a development that adds long‑term pipeline upside if the program shows activity. Read More.
• Positive Sentiment: Post‑marketing safety study for IMLYGIC in melanoma reached completion — reduces an uncertainty from the label/safety perspective and may support that asset’s commercial outlook. Read More.
• Neutral Sentiment: Guggenheim raised its price target to $347 but kept a Neutral rating; the new PT still implies downside versus the current price, creating mixed signals for investors. Read More.
• Neutral Sentiment: Deutsche Bank moved its target to $295 and maintained a Hold — another measured call that tempers the enthusiasm from Buy-rated upgrades. Read More.
• Neutral Sentiment: Market commentary notes rotation into defensive/health names and institutional buying as contributors to the stock’s move to multi‑month highs — a broader-market technical tailwind rather than company‑specific news. Read More.
• Negative Sentiment: CVS said it will replace Amgen’s and Lilly’s bone‑disease treatments with lower‑cost alternatives on some preferred drug lists starting April 1 — a material commercial headwind for the affected product sales. Read More.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.